Bispecific Antibodies for In Vivo Research

Bispecific antibodies are an advanced class of biologics engineered to bind two distinct antigens or epitopes simultaneously. Unlike single-target monoclonal antibodies, bispecifics can bring together two molecules, or even two cell types, to create unique biological interactions. By bridging cellular interactions or co‑targeting molecular pathways, Bio X Cell's in vivo-ready bispecifics offer a powerful strategy for immune cell redirection, dual‑pathway blockade, payload delivery, and enhanced selectivity.

Applications in drug discovery and translational research

In drug discovery and translational research, bispecific antibodies are increasingly used to:

Redirect T cells or NK cells for targeted cytotoxicity
Engage multiple immune checkpoints
Block redundant or compensatory signalling pathways
Improve tumour specificity and reduce off‑target effects
Explore novel immune‑therapeutic mechanisms in oncology, autoimmunity, and infectious disease

Scroll to contact form

Bio X Cell’s bispecific solutions

Bispecifics are dual-target validated, high purity and in vivo ready, allowing researchers to run studies immediately without waiting for custom constructs.

Key features

Defined dual‑target binding: Recombinant bispecific formats engaging two defined targets
Format flexibility: Knob‑into‑hole, head‑to‑tail and BiTE‑style architectures available
In-vivo-ready: Carrier‑free formulations for in vivo and advanced in vitro models
Fc‑modified options: Reduced Fc effector function for target‑driven studies
Low endotoxin: Typically ≤ 1 EU/mg with lot‑specific QC testing
Pathogen screened: Murine pathogen screening with datasheet documentation

Representative target pairs and applications

Target pair	Therapeutic analogue	Species	Applications
CD3 x BCMA	Teclistamab	Human	Preclinical modeling of bispecific T-cell engager activity in multiple myeloma.
CD3 x GPRC5D	Talquetamab	Human	Evaluating dual-targeting strategies for resistant myeloma and T-cell redirection.
EGFR x MET	Amivantamab	Human	Studying receptor crosstalk, ligand competition, and resistance mechanism in epithelial tumors.
CD3 x CD20	Epcortimab*	Mouse	Investigating dual B-cell targeting and T-cell engagement in syngeneic lymphoma models.
PD-1 x VEGF	Ivonescimab*	Mouse	Modeling immune checkpoint and angiogenic pathway interplay in mouse tumor studies.

*Engineered mouse bispecifics designed to dually target murine antigens corresponding to the therapeutic targets listed above

Explore the full bispecific portfolio

Anti-Mouse Bispecific Antibodies: In vivo ready reagents designed for mouse models, replicating clinical constructs to enable predictive mechanism-of-action and efficacy studies.
Anti-Human Bispecific Biosimilars: Biosimilars that mirror clinical therapeutics for accurate benchmarking and translational validation across scales.
Custom Bispecific Engineering: Flexible, expert-guided construct design and scalable production to accelerate your bispecific antibody program.

Tested for purity, binding specificity, and dual-target function, bispecific antibodies from Bio X Cell support diverse applications including dual checkpoint blockade, immune-cell redirection, and tumor microenvironment modeling.

Featured products

Cat-No.	Item	Size	Price (CHF)
CPB500-1MG	Bispecific mouse IgG2a (LALA-PG)-scFv, kappa isotype control	1 mg	price on request
CPB501-1MG	Bispecific anti mouse PD-1 x anti mouse VEGF-A (LALA-PG)	1 mg	price on request
CPB502-1MG	Bispecific anti mouse CD3 x anti mouse CD20 (LALA-PG)	1 mg	price on request
SIM0067-100MG	InVivoSIM anti human CD3 x BCMA (Teclistamab Biosimilar)	100 mg	price on request
SIM0081-100MG	InVivoSIM anti human EGFR x MET (Amivantamab Biosimilar)	100 mg	price on request
SIM0069-100MG	InVivoSIM anti human CD3 x GPRC5D (Talquetamab Biosimilar)	100 mg	price on request